Medicine, Health & Food

Medicine, Health & Food

Archive
Join as an Editor/Reviewer

THE DETECTION OF ELEVATED CHOLINE METABOLITE IN MAGNETIC RESONANCE SPECTROSCOPY TO DIFFERENTIATE BETWEEN BENIGN AND MALIGNANT BONE TUMOR

Volume: 60  ,  Issue: 1 , September    Published Date: 21 September 2020
Publisher Name: IJRP
Views: 63  ,  Download: 15
DOI: 10.47119/IJRP100601920201410

Authors

# Author Name
1 Rizky Nur Putra
2 Paulus Rahardjo
3 Rosy Setiawati

Abstract

Objective: This study was aimed to determine the accuracy of elevated choline metabolite in Magnetic Resonance Spectroscopy (MRS) at bone tumor to differentiate between benign and malignant according to their pathology result. Materials and Methods: A retrospective study of 40 samples consisted of benign and malignant bone tumor patients who met the inclusion criteria, who had MRS examination from January 2019 to January 2020. Elevated choline metabolite was used to differentiate between benign and malignant lesions based on their pathological result. From this study, we got sensitivity value, specificity value, PPV(positive predictive value), NPV(negative predictive value) and accuracy value. Results: The total number of patients were 40 who had bone tumor. The 11 benign tumors, consisted of 8 giant cell tumors (GCT), 1 aneurysmal bone cyst (ABC) and 2 abscesses on MRS the 7 of 8 GCTs and 1 ABC did not show elevated choline metabolite in MRS. One GCT and 2 abscesses showed elevated choline metabolite in their respective MRS. The 29 malignant cases consisted of 19 osteosarcomas, 2 chondrosarcomas, 2 plasmacytomas, 1 malignant GCT and 5 metastatic bone diseases. All but one case did not show elevated choline metabolite in their MRS and that was osteosarcoma. Conclusion: Elevated choline metabolite of proton MRS have higher sensitivity, specificity, PPV, NPV and accuracy to differentiate between benign and malignant bone tumor according to pathological result.

Keywords

  • recommandation engine
  • References

    Abeloff MD, N. J. (2007). Abeloff Clinical Oncology. Churchill livingstone: Elsevier.

    Chien-Kuo Wang, C.-W. L.-J.-H.-C.-B. (2004). Characterization of Bone and and Soft-Tissue Tumors with in Vivo 1H MR Spectroscopy : Initial Results1. Musculoskeletal Imaging, 232(2), 599-605. doi:10.1148/radiol.2322031441

    Drapé, J.-L. (2013). Advances in magnetic resonance imaging of musculoskeletal tumours. Orthopaedics & Traumatology: Surgery & Research, S115-S123.

    Fayad LM, B. P. (2007). Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy. AJR Am J Roentgenol, 188(6), 1513-1520.

    Jing Zhang, K. C. (2013). Study of single voxel1H MR spectroscopy of bone tumors: Differentiation of benign from malignant tumors. European Journal of Radiology, 82, 2124– 2128. doi:10.1016/j.ejrad.2011.11.033

    Laura M. Fayad, M. A. (2012). Musculoskeletal Tumors: How to Use Anatomic, Functional, and Metabolic MR Techniques. Radiology RSNA, 265(2), 340-356.

    Pedro A. Gondim Teixeira, M. B.-l. (2015). Advanced Techniques in Musculoskeletal Oncology: Perfusion, Diffusion, and. Semin Musculoskelet Radiol, 19, 463-474.

    QI Zi-hua, L. C.-f.-f.-x. (2009). Preliminary study of 3T 1H MR spectroscopy in bone and soft. (W. De, Ed.) Chinese Medical Journal, 122(1), 39-43. doi:10.3760/cma.j.issn.0366-6999.2009.01.008

    Ty K. Subhawong, X. W. (2011). Proton MR Spectroscopy in Metabolic Assessment of Musculoskeletal Lesions. Mu s c u l o s k e l e t a l I ma g i n g • R e v i ew, 162-172.

    Ty K. Subhawong, X. W. (2012). Proton MR Spectroscopy in Metabolic Assessment of Musculoskeletal Lesions. Musculoskeletal Imaging Review, 214(2), 162-172.